• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by MultiPlan Corporation

    8/5/24 7:06:26 PM ET
    $MPLN
    Business Services
    Consumer Discretionary
    Get the next $MPLN alert in real time by email
    S-8 1 august2024s-8toregistergar.htm S-8 Document

    As filed with the Securities and Exchange Commission on August 5, 2024
    Registration No. 333-
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
     FORM S-8
    REGISTRATION STATEMENT
    UNDER THE SECURITIES ACT OF 1933
     
     
     MultiPlan Corporation
    (Exact name of registrant as specified in its charter)
     
     
     Delaware
    (State or other jurisdiction of
    incorporation or organization) 
    83-3536151
    (I.R.S. Employer
    Identification Number) 

     
    115 Fifth Avenue
    New York, New York 10003
    (212) 967-1009
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
     
     
    Inducement Option Award
    Inducement Restricted Stock Units
    (Full title of the plan)
     
     
    Travis S. Dalton
    Chief Executive Officer
    MultiPlan Corporation
    115 Fifth Avenue
    New York, New York 10003
    Tel: (212) 780-2000
    (Name, address, including zip code, and telephone number, including area code, of agent for service)
     
     
     With copies to:  
    William B. Brentani
    Heidi Mayon
    Simpson Thacher & Bartlett LLP
    2475 Hanover Street
    Palo Alto, California 94304
    Tel: (650) 251-5000
    Fax: (650) 251-5002
     
     



    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filerxAccelerated filer
    o
    Non-accelerated filer
    o
    Smaller reporting company
    o
    Emerging growth company
    o
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

    EXPLANATORY NOTE

    MultiPlan Corporation (the “Registrant”, the “Company”, “we” or “us”) has prepared this Registration Statement in accordance with the requirements of Form S-8 under the United States Securities Act of 1933, as amended (the “Securities Act”), to register (i) (a) 4,901,960 shares of its Class A common stock, par value $0.0001 per share (the “Common Stock”) issuable pursuant to a stock option award and (b) 3,571,428 shares of Common Stock underlying restricted stock units, granted to Douglas Garis, Executive Vice President, Chief Financial Officer and Treasurer, to induce such individual to accept employment with the Registrant in accordance with Rule 303A.08 of the New York Stock Exchange (“NYSE”) Listed Company Manual (collectively, the “Garis Inducement Awards”), and (ii) 1,928,571 shares of Common Stock underlying restricted stock units, granted to William Mintz, Senior Vice President, Corporate Affairs and Strategy, to induce such individual to accept employment with the Registrant in accordance with Rule 303A.08 of the NYSE Listed Company Manual (the “Mintz Inducement Awards” and, together with the Garis Inducement Awards, the “Inducement Awards”). The Inducement Awards were granted on August 5, 2024.

    The Inducement Awards were approved by the Registrant’s Board of Directors in compliance with and in reliance on Rule 303A.08 of the NYSE List Company Manual. The Inducement Awards were granted outside of the Registrant’s existing equity incentive plans.
    PART I
     
    The information specified in Item 1 and Item 2 of Part I of this Registration Statement is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I will be delivered to each of Mr. Garis and Mr. Mintz pursuant to the respective Inducement Awards as required by Rule 303A.08.
     
    PART II
     
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
     
    Item 3.Incorporation of Documents by Reference.
    The following documents filed with the Commission by the Company pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are hereby incorporated by reference in this Registration Statement:

    (a) The Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on February 29, 2024 (the “Form 10-K”);

    (b) The Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2024 and June 30, 2024;

    (c) The Company's Current Reports on Form 8-K filed with the Commission January 3, 2024, January 4, 2024, March 7, 2024 (excluding such portion furnished under Item 7.01 and any such exhibits included with such Item), March 29, 2024 (excluding such portion furnished under Item 7.01 and any such exhibits included with such Item),



    April 26, 2024, May 10, 2024 and August 2, 2024 (only with respect to information filed under Item 5.02 and Exhibits 10.1 and 10.2 filed under Item 9.01);

    (d) All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act, since the end of the fiscal year covered by the Company’s 10-K referred to in (a) above, excluding any documents or portions of such documents that are furnished under Item 2.02 or Item 7.01 of a current report on Form 8-K and any exhibits included with such Item; and

    (e) The description of the Company’s securities contained in Exhibit 4.12 of the Company's 10-K referred to in (a) above, including any amendment or report filed for the purpose of updating such description.

    All documents that the Company subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this Registration Statement (except for any portions of the Company’s Current Reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission) and prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
     
    Item 4.Description of Securities.
     
    Not applicable.
     
    Item 5.Interests of Named Experts and Counsel.
     
    Not applicable.
     
    Item 6.Indemnification of Directors and Officers.
     
    Section 102(b)(7) of the General Corporation Law of the State of Delaware (“DGCL”) allows a corporation to provide in its certificate of incorporation that a director of the corporation will not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except where the director breached the duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. The Registrant’s second amended and restated certificate of incorporation provides for this limitation of liability.

    Section 145 of the DGCL, provides, among other things, that a Delaware corporation may indemnify any person who was, is or is threatened to be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was unlawful. A Delaware corporation may indemnify any persons who were or are a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or agent of another corporation or enterprise. The indemnity



    may include expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit, provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interests, provided further that no indemnification is permitted without judicial approval if the officer, director, employee or agent is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses (including attorneys’ fees) which such officer or director has actually and reasonably incurred.

    Section 145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation would otherwise have the power to indemnify such person under Section 145.

    The Registrant’s amended and restated bylaws provide that the Registrant must indemnify and advance expenses to our directors and officers to the full extent authorized by the DGCL.

    The Registrant has entered into indemnification agreements with each of its directors and executive officers. Such agreements may require the Registrant, among other things, to advance expenses and otherwise indemnify its executive officers and directors against certain liabilities that may arise by reason of their status or service as executive officers or directors, to the fullest extent permitted by law. The Registrant intends to enter into indemnification agreements with any new directors and executive officers in the future.

    The indemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute, any provision of the Registrant’s second amended and restated certificate of incorporation, the Registrant’s amended and restated bylaws, agreement, vote of stockholders or disinterested directors or otherwise. Notwithstanding the foregoing, the Registrant shall not be obligated to indemnify a director or officer in respect of a proceeding (or part thereof) instituted by such director or officer, unless such proceeding (or part thereof) has been authorized by the Board pursuant to the applicable procedure outlined in the Registrant’s amended and restated bylaws.

    Section 174 of the DGCL provides, among other things, that a director, who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption, may be held jointly and severally liable for such actions. A director who was either absent when the unlawful actions were approved or dissented at the time may avoid liability by causing his or her dissent to such actions to be entered in the books containing the minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts.

    The Registrant maintains and expects to maintain standard policies of insurance that provide coverage (1) to its directors and officers against loss rising from claims made by reason of breach of duty or other wrongful act and (2) to the Registrant with respect to indemnification payments that the Registrant may make to such directors and officers.

    These provisions may discourage stockholders from bringing a lawsuit against the Registrant’s directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit the Registrant and its stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent the Registrant pays the costs of settlement and damage awards against officers and directors pursuant to these indemnification provisions.

    The Registrant believes that these provisions, the insurance and the indemnity agreements are necessary to attract and retain talented and experienced officers and directors.




    Insofar as indemnification for liabilities arising under the Securities Act, may be permitted to directors or executive officers, the Registrant has been informed that in the opinion of the Commission such indemnification is against public policy and is therefore unenforceable.

     
    Item 7.Exemption from Registration Claimed.
     
    Not applicable.
     
    Item 8.Exhibits.
     
    The following exhibits are filed as part of this Registration Statement:
     
    Exhibit
    Number
     Description of Document
    5.1* 
    Opinion of Simpson Thacher & Bartlett LLP
    23.1* 
    Consent of PricewaterhouseCoopers LLP
    23.2* 
    Consent of Simpson Thacher & Bartlett LLP (included as part of Exhibit 5.1)
    107*
    Filing Fee Table
             
    * Filed herewith



     




    SIGNATURES
     
    Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on the 5th day of August, 2024.

     
      
    MultiPlan Corporation
    (Registrant)
      
    By:/s/ Travis Dalton
    Name:Travis Dalton
    Title:President and Chief Executive Officer (Principal Executive Officer)

     




    Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons in the capacities and on the dates indicated.

    Signature Title(s)Date
       
    /s/ Travis Dalton President, Chief Executive Officer (Principal Executive Officer) and DirectorAugust 5, 2024
    Travis Dalton 
       
    /s/ Douglas Garis Executive Vice President and Chief Financial Officer (Principal Financial Officer)August 5, 2024
    Douglas Garis 
       
    /s/ Gerald J. Kozel Senior Vice President and Chief Accounting Officer (Principal Accounting Officer)August 5, 2024
    Gerald J. Kozel 
       
    /s/ Dale A. White Executive Chair of the Board of DirectorsAugust 5, 2024
    Dale A. White  
       
    /s/ Allen R. Thorpe Lead Independent DirectorAugust 5, 2024
    Allen R. Thorpe  
    /s/ Glenn R. AugustDirectorAugust 5, 2024
    Glenn R. August
    /s/ Richard A. ClarkeDirectorAugust 5, 2024
    Richard A. Clarke
    /s/ Anthony Colaluca, Jr.DirectorAugust 5, 2024
    Anthony Colaluca, Jr.
    /s/    C. Martin Harris
    DirectorAugust 5, 2024
    C. Martin Harris
    /s/    Julie D. KlapsteinDirectorAugust 5, 2024
    Julie D. Klapstein
    /s/    Michael S. KleinDirectorAugust 5, 2024
    Michael S. Klein
    /s/    P. Hunter PhilbrickDirectorAugust 5, 2024
    P. Hunter Philbrick
    /s/    John M. PrinceDirectorAugust 5, 2024
    John M. Prince
       
     

    Get the next $MPLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MPLN

    DatePrice TargetRatingAnalyst
    6/26/2024$2.00Neutral
    Piper Sandler
    12/13/2022$3.00 → $2.00Buy → Neutral
    Citigroup
    7/12/2022$6.50Neutral
    Goldman
    12/20/2021$9.00 → $7.00Buy
    Citigroup
    11/11/2021$7.00 → $6.00Equal-Weight
    Barclays
    10/4/2021$9.00Buy
    Citigroup
    8/20/2021$9.00Buy
    Tigress Financial
    More analyst ratings

    $MPLN
    SEC Filings

    View All

    SEC Form 10-K filed by MultiPlan Corporation

    10-K - Claritev Corp (0001793229) (Filer)

    2/26/25 7:50:06 AM ET
    $MPLN
    Business Services
    Consumer Discretionary

    MultiPlan Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Claritev Corp (0001793229) (Filer)

    2/25/25 6:21:17 AM ET
    $MPLN
    Business Services
    Consumer Discretionary

    MultiPlan Corporation filed SEC Form 8-K: Other Events

    8-K - Claritev Corp (0001793229) (Filer)

    2/24/25 8:02:11 AM ET
    $MPLN
    Business Services
    Consumer Discretionary

    $MPLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $MPLN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $MPLN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $MPLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ClearNote Health's Avantect® Pancreatic Cancer Test Now Available to Health Plan Members Accessing Claritev's National PPO Networks

    Latest agreement expands access to the PHCS and MultiPlan Networks ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced an agreement with Claritev, Inc. ("Claritev") (NYSE:CTEV), previously MultiPlan, Inc. (NYSE:MPLN), a technology and data insights company focused on making healthcare more affordable, transparent, and fair for all. As part of the agreement, ClearNote Health's Avantect® Pancreatic Cancer Test will now be available to health plan members accessing Claritev's national PHCS and MultiPlan Networks. While early detection has vastly improved survival rates for many types of cancer, pancreatic cancer is often diagnos

    3/12/25 8:03:00 AM ET
    $CTEV
    $MPLN
    Real Estate
    Business Services
    Consumer Discretionary

    Claritev Reports Fourth Quarter and Full Year 2024 Results with Initial Guidance for Full Year 2025

    Q4 2024 Revenues of $232.1 million, Net Loss of $138.0 million and Adjusted EBITDA of $141.6 million Full Year 2024 Revenues of $930.6 million, Net Loss of $1,645.8 million and Adjusted EBITDA of $576.7 million Full Year 2025 Revenues guidance of (2)% to flat as compared to FY 2024 and FY 2025 Adjusted EBITDA % guidance of 62.5% to 63.5% Claritev Corporation ("Claritev" or the "Company") (NYSE:MPLN), formerly known as MultiPlan, a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the fourth quarter and full year ended December 31, 2024. Chairman, CEO and President Travis Dalt

    2/25/25 6:00:00 AM ET
    $MPLN
    Business Services
    Consumer Discretionary

    Claritev Provides Oracle Cloud HCM Customers with Actionable Insights for Healthcare Cost Optimization and Plan Design

    Claritev's Award-Winning Analytics Solution, BenInsights®, is Powered by Oracle Cloud and Now Available in the Oracle Cloud Marketplace Claritev Corporation ("Claritev" or the "Company") (NYSE:MPLN), formerly known as MultiPlan, a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, and an Oracle partner, announced today its analytics solution, BenInsights®, has achieved Integrated with Oracle Cloud Expertise and is now available in the Oracle Cloud Marketplace, offering added value to Oracle Cloud customers. The BenInsights platform enables visibility into benefit plan performance and compliance responsibilities for employers of

    2/21/25 8:00:00 AM ET
    $MPLN
    Business Services
    Consumer Discretionary

    Amendment: SEC Form 4 filed by SVP, Chief Information Officer Kim Michael

    4/A - MultiPlan Corp (0001793229) (Issuer)

    12/13/24 4:28:52 PM ET
    $MPLN
    Business Services
    Consumer Discretionary

    SVP, Chief Information Officer Kim Michael bought $249,588 worth of shares (40,000 units at $6.24), increasing direct ownership by 3% to 1,312,772 units (SEC Form 4)

    4 - MultiPlan Corp (0001793229) (Issuer)

    11/19/24 4:35:27 PM ET
    $MPLN
    Business Services
    Consumer Discretionary

    SVP, Chief Growth Officer Misencik Tiffani was granted 95,328 shares (SEC Form 4)

    4 - MultiPlan Corp (0001793229) (Issuer)

    10/16/24 5:01:01 PM ET
    $MPLN
    Business Services
    Consumer Discretionary

    SVP, Chief Information Officer Kim Michael bought $249,588 worth of shares (40,000 units at $6.24), increasing direct ownership by 3% to 1,312,772 units (SEC Form 4)

    4 - MultiPlan Corp (0001793229) (Issuer)

    11/19/24 4:35:27 PM ET
    $MPLN
    Business Services
    Consumer Discretionary

    SVP, Corp. Affairs/Strategy Mintz William B. bought $104,359 worth of shares (278,165 units at $0.38), increasing direct ownership by 14% to 2,206,736 units (SEC Form 4)

    4 - MultiPlan Corp (0001793229) (Issuer)

    8/8/24 4:30:55 PM ET
    $MPLN
    Business Services
    Consumer Discretionary

    Pres., Chief Executive Officer Dalton Travis bought $185,000 worth of shares (500,000 units at $0.37), increasing direct ownership by 11% to 5,004,504 units (SEC Form 4)

    4 - MultiPlan Corp (0001793229) (Issuer)

    8/7/24 6:05:14 PM ET
    $MPLN
    Business Services
    Consumer Discretionary

    Piper Sandler initiated coverage on MultiPlan with a new price target

    Piper Sandler initiated coverage of MultiPlan with a rating of Neutral and set a new price target of $2.00

    6/26/24 7:57:01 AM ET
    $MPLN
    Business Services
    Consumer Discretionary

    MultiPlan downgraded by Citigroup with a new price target

    Citigroup downgraded MultiPlan from Buy to Neutral and set a new price target of $2.00 from $3.00 previously

    12/13/22 9:12:38 AM ET
    $MPLN
    Business Services
    Consumer Discretionary

    Goldman initiated coverage on MultiPlan with a new price target

    Goldman initiated coverage of MultiPlan with a rating of Neutral and set a new price target of $6.50

    7/12/22 7:32:35 AM ET
    $MPLN
    Business Services
    Consumer Discretionary

    $MPLN
    Leadership Updates

    Live Leadership Updates

    View All

    MultiPlan Appoints Tiffani Misencik to Drive Strategic Growth

    Tiffani Misencik Named Chief Growth Officer in New Executive Leadership Role MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading provider of data-driven cost management solutions that deliver transparency and promote fairness, quality and affordability to the U.S. healthcare industry, today announced a new addition to its executive leadership team to support the next phase of the Company's strategic growth. Tiffani Misencik has been appointed Chief Growth Officer. In this newly created role, Misencik will oversee MultiPlan's sales and revenue growth strategy across all market segments. She will lead the company's efforts in client acquisition, client management, an

    10/22/24 2:00:00 PM ET
    $MPLN
    Business Services
    Consumer Discretionary

    MultiPlan Makes Fortune's Best Workplaces in Health Care List for Second Year in a Row

    MultiPlan Corporation (NYSE:MPLN) ("MultiPlan" or the "Company"), a leading provider of technology and data-enabled cost management, payment, and revenue integrity solutions to the U.S. health care industry, is honored to announce it has been named in the 2024 Fortune Best Workplaces in Health Care™ List. based on its 2023-2024 Great Place to Work® Certification™ results. This is the second time MultiPlan has been named in the Best Workplaces in Health Care list. Earning a spot means that MultiPlan is one of the best companies to work for in the country. The Best Workplaces in Health Care list is based on analysis of survey responses from over 185,000 employees from Great Place To Work Cer

    9/12/24 8:30:00 AM ET
    $MPLN
    Business Services
    Consumer Discretionary

    MultiPlan Announces CFO Transition

    MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading value-added provider of data analytics and technology-enabled end-to-end cost management, as well as payment and revenue integrity solutions to the U.S. healthcare industry, announced today its CFO transition plan and named Doug Garis as EVP and CFO, effective August 5, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240731993142/en/Doug Garis named EVP and CFO of MultiPlan (Photo: Business Wire) Jim Head, who has served as EVP and CFO of MultiPlan since November 2021, will transition to a Strategic Advisor role to the Company through the end of the

    8/1/24 6:00:00 AM ET
    $DOOR
    $MPLN
    $ORCL
    Forest Products
    Basic Materials
    Business Services
    Consumer Discretionary

    $MPLN
    Financials

    Live finance-specific insights

    View All

    Claritev Reports Fourth Quarter and Full Year 2024 Results with Initial Guidance for Full Year 2025

    Q4 2024 Revenues of $232.1 million, Net Loss of $138.0 million and Adjusted EBITDA of $141.6 million Full Year 2024 Revenues of $930.6 million, Net Loss of $1,645.8 million and Adjusted EBITDA of $576.7 million Full Year 2025 Revenues guidance of (2)% to flat as compared to FY 2024 and FY 2025 Adjusted EBITDA % guidance of 62.5% to 63.5% Claritev Corporation ("Claritev" or the "Company") (NYSE:MPLN), formerly known as MultiPlan, a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the fourth quarter and full year ended December 31, 2024. Chairman, CEO and President Travis Dalt

    2/25/25 6:00:00 AM ET
    $MPLN
    Business Services
    Consumer Discretionary

    MultiPlan Corporation Announces Fourth Quarter and Full Year 2024 Earnings Conference Call

    MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading provider of technology and data solutions that improve affordability, quality and transparency in healthcare, announced today that it will release its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, and hold its conference call that morning at 8:00 am Eastern Time. To join the conference call, please pre-register using the link below. Participants who pre-register will receive a calendar invitation with call access details including a unique pin. Pre-registration may be completed at any time up to and following the call start time. To pre-register, go to: https://www.netroadsho

    1/28/25 8:30:00 AM ET
    $MPLN
    Business Services
    Consumer Discretionary

    MultiPlan Reports Third Quarter 2024 Results and Updates 2024 Guidance

    – Q3 2024 Revenues of $230.5 million, Net Loss of $391.5 million (including a $361.6 million impairment of goodwill and indefinite-lived intangibles), and Adjusted EBITDA of $141.6 million – Identified potential medical cost savings of approximately $6.4 billion in Q3 2024, up 10% from Q3 2023 and up 3% from Q2 2024 MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading provider of data-driven cost management solutions that deliver transparency and promote fairness, quality and affordability to the U.S. healthcare industry, today reported financial results for the third quarter ended September 30, 2024 and updated its full-year 2024 guidance. CEO Travis Dalton said,

    11/5/24 6:00:00 AM ET
    $MPLN
    Business Services
    Consumer Discretionary

    $MPLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MultiPlan Corporation

    SC 13G/A - MultiPlan Corp (0001793229) (Subject)

    11/12/24 4:00:27 PM ET
    $MPLN
    Business Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by MultiPlan Corporation

    SC 13G/A - MultiPlan Corp (0001793229) (Subject)

    11/4/24 3:13:44 PM ET
    $MPLN
    Business Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by MultiPlan Corporation

    SC 13G/A - MultiPlan Corp (0001793229) (Subject)

    11/4/24 1:43:06 PM ET
    $MPLN
    Business Services
    Consumer Discretionary